| scholarly article | Q13442814 |
| P50 | author | Paul J Thornalley | Q56810389 |
| P2093 | author name string | I Giardino | |
| M Brownlee | |||
| M Shinohara | |||
| S R Thorpe | |||
| J Onorato | |||
| P Beisswenger | |||
| P2860 | cites work | The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life | Q24527362 |
| Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes | Q24627259 | ||
| Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure | Q24634002 | ||
| In vivo glycation of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme: identification of glycation sites | Q28305676 | ||
| Reduction of trioses by NADPH-dependent aldo-keto reductases. Aldose reductase, methylglyoxal, and diabetic complications | Q28319032 | ||
| N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins | Q28378989 | ||
| Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter | Q29614259 | ||
| Advanced protein glycosylation in diabetes and aging | Q34298835 | ||
| Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose | Q34321118 | ||
| S-(N-aryl-N-hydroxycarbamoyl)glutathione derivatives are tight-binding inhibitors of glyoxalase I and slow substrates for glyoxalase II. | Q34330523 | ||
| 3-Deoxyfructose concentrations are increased in human plasma and urine in diabetes | Q34332726 | ||
| Cloning and characterization of human colon glyoxalase-I. | Q34361639 | ||
| Transsynaptic neuronal loss induced in hippocampal slice cultures by a herpes simplex virus vector expressing the GluR6 subunit of the kainate receptor | Q36397586 | ||
| Two asialoglycoprotein receptor polypeptides in human hepatoma cells | Q36427390 | ||
| Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia | Q36851040 | ||
| BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells | Q37353111 | ||
| Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli beta-galactosidase | Q37689072 | ||
| Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications | Q39506963 | ||
| Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. | Q40730866 | ||
| Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus | Q40759611 | ||
| Hyperglycemic pseudohypoxia and diabetic complications. | Q40908737 | ||
| Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification--a role in pathogenesis and antiproliferative chemotherapy. | Q41148677 | ||
| Functional characterization of the rat GAP-43 promoter | Q41486257 | ||
| N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction | Q42555798 | ||
| Probing the active site of glyoxalase I from human erythrocytes by use of the strong reversible inhibitor S-p-bromobenzylglutathione and metal substitutions | Q45233851 | ||
| Measurement of acetol in serum. | Q51637439 | ||
| High D-glucose-induced changes in endothelial Ca2+/EDRF signaling are due to generation of superoxide anions. | Q54140931 | ||
| Negative Association between Erythrocyte Reduced Glutathione Concentration and Diabetic Complications | Q60786668 | ||
| Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins | Q60786677 | ||
| Glyoxalase System in Clinical Diabetes Mellitus and Correlation with Diabetic Complications | Q60786679 | ||
| Modification of the glyoxalase system in streptozotocin-induced diabetic rats | Q60786696 | ||
| The assay of methylglyoxal in biological systems byderivatization with 1,2-diamino-4,5-dimethoxybenzene | Q60786717 | ||
| Amadori rearrangement potential of hemoglobin at its glycation sites is dependent on the three-dimensional structure of protein | Q67974305 | ||
| Sensitive determination of D-lactic acid in biological samples by high-performance liquid chromatography | Q68062678 | ||
| Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form | Q69208934 | ||
| Glyoxalase I from mouse liver | Q70548265 | ||
| Increased endocytosis in retinal vascular endothelial cells grown in high glucose medium is modulated by inhibitors of nonenzymatic glycosylation | Q70953748 | ||
| The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions | Q71070390 | ||
| Method for determination of free intracellular and extracellular methylglyoxal in animal cells grown in culture | Q71138879 | ||
| Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM | Q71442189 | ||
| Pathways of Formation of Glycoxidation Products during Glycation of Collagen | Q71786493 | ||
| Increase in 3-deoxyglucosone levels in diabetic rat plasma. Specific in vivo determination of intermediate in advanced Maillard reaction | Q72108149 | ||
| Retinal vascular endothelial cell endocytosis increases in early diabetes | Q72171952 | ||
| Receptor-mediated endocytic uptake of methylglyoxal-modified serum albumin. Competition with advanced glycation end product-modified serum albumin at the advanced glycation end product receptor | Q72352184 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | macromolecule | Q178593 |
| endocytosis | Q189814 | ||
| hyperglycemia | Q271993 | ||
| overexpression | Q61643320 | ||
| P304 | page(s) | 1142-1147 | |
| P577 | publication date | 1998-03-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis | |
| P478 | volume | 101 |
| Q42862729 | A Diverse Series of Substituted Benzenesulfonamides as Aldose Reductase Inhibitors with Antioxidant Activity: Design, Synthesis, and in Vitro Activity |
| Q53811353 | A bis-Schiff base of isatin improves methylglyoxal mediated insulin resistance in skeletal muscle cells. |
| Q37094883 | A high-salt diet further impairs age-associated declines in cognitive, behavioral, and cardiovascular functions in male Fischer brown Norway rats |
| Q37003623 | AGE restriction in diabetes mellitus: a paradigm shift |
| Q51747235 | AGE-RAGE Stress, Stressors, and Antistressors in Health and Disease. |
| Q40940923 | Accumulation of alpha-oxoaldehydes during oxidative stress: a role in cytotoxicity |
| Q38197337 | Activity, regulation, copy number and function in the glyoxalase system |
| Q36965274 | Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes. |
| Q37149382 | Advanced glycation end products and diabetic foot disease |
| Q37930514 | Advanced glycation end products and diabetic retinopathy |
| Q46613227 | Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine |
| Q36643573 | Advanced glycation end products: Key players in skin aging? |
| Q38081119 | Advanced glycation end products: role in pathology of diabetic cardiomyopathy |
| Q46542915 | Advanced glycosylation end products in skin, serum, saliva and urine and its association with complications of patients with type 2 diabetes mellitus |
| Q34387932 | Aldolase B knockdown prevents high glucose-induced methylglyoxal overproduction and cellular dysfunction in endothelial cells. |
| Q47721742 | Aldose reductase: a window to the treatment of diabetic complications? |
| Q40346041 | Amelioration of oxidant stress by the defensin lysozyme |
| Q36492859 | An advanced glycation end product (AGE)-receptor for AGEs (RAGE) axis restores adipogenic potential of senescent preadipocytes through modulation of p53 protein function |
| Q42326942 | Analysis of Methylglyoxal Metabolism in CHO Cells Grown in Culture |
| Q35568131 | Angioblast Derived from ES Cells Construct Blood Vessels and Ameliorate Diabetic Polyneuropathy in Mice |
| Q34441960 | Angiogenesis impairment in diabetes: role of methylglyoxal-induced receptor for advanced glycation endproducts, autophagy and vascular endothelial growth factor receptor 2 |
| Q37181170 | Arabidopsis thaliana GLX2-1 contains a dinuclear metal binding site, but is not a glyoxalase 2. |
| Q38199486 | Association of oxidative stress to the genesis of anxiety: implications for possible therapeutic interventions |
| Q84520313 | Association of two glyoxalase I gene polymorphisms with nephropathy and retinopathy in Type 2 diabetes |
| Q40802125 | Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes? |
| Q29012485 | Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy |
| Q28131781 | Biochemistry and molecular cell biology of diabetic complications |
| Q52939905 | CHOP deficiency prevents methylglyoxal-induced myocyte apoptosis and cardiac dysfunction. |
| Q34355343 | Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function |
| Q36687957 | Cellular mechanisms and signalling pathways activated by high glucose and AGE-albumin in the aortic endothelium |
| Q42583958 | Characterisation of glyoxalase I in a streptozocin-induced mouse model of diabetes with painful and insensate neuropathy |
| Q46817492 | Common polymorphisms in the glyoxalase-1 gene and their association with pro-thrombotic factors |
| Q57073373 | Compensatory mechanisms for methylglyoxal detoxification in experimental & clinical diabetes |
| Q36283819 | Correlations between Photodegradation of Bisretinoid Constituents of Retina and Dicarbonyl Adduct Deposition |
| Q33267290 | Critical role of methylglyoxal and AGE in mycobacteria-induced macrophage apoptosis and activation |
| Q38070906 | Current therapeutic interventions in the glycation pathway: evidence from clinical studies |
| Q43593904 | Cytotoxic action of methylglyoxal on insulin-secreting cells |
| Q47105930 | Deletion of FoxO1, 3, and 4 in Osteoblast Progenitors Attenuates the Loss of Cancellous Bone Mass in a Mouse Model of Type 1 Diabetes |
| Q35172873 | Diabetes and cancer: Looking at the multiligand/RAGE axis. |
| Q38070160 | Diabetes-related adduct formation and retinopathy. |
| Q79291119 | Diabetic hepatosclerosis: a novel entity or a rare form of nonalcoholic fatty liver disease? |
| Q33921581 | Diabetic osteopenia by decreased β-catenin signaling is partly induced by epigenetic derepression of sFRP-4 gene |
| Q37072018 | Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent? |
| Q89552373 | Dicarbonyl Stress and S-Glutathionylation in Cerebrovascular Diseases: A Focus on Cerebral Cavernous Malformations |
| Q92084106 | Dicarbonyl Stress at the Crossroads of Healthy and Unhealthy Aging |
| Q46613111 | Dicarbonyl stress and apoptosis of vascular cells: prevention by alphaB-crystallin |
| Q47632182 | Dicarbonyl stress and glyoxalase enzyme system regulation in human skeletal muscle. |
| Q42273415 | Dicarbonyl stress in clinical obesity |
| Q37156152 | Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics |
| Q40047034 | Dicarbonyls linked to damage in the powerhouse: glycation of mitochondrial proteins and oxidative stress |
| Q37733102 | Dietary hyperglycemia, glycemic index and metabolic retinal diseases |
| Q39725004 | Dietary phenolic acids attenuate multiple stages of protein glycation and high-glucose-stimulated proinflammatory IL-1beta activation by interfering with chromatin remodeling and transcription in monocytes |
| Q44367856 | Different influences of hyperglycemic duration on phosphorylated extracellular signal-regulated kinase 1/2 in rat heart |
| Q36824440 | Distribution of glyoxalase I polymorphism among Zuni Indians: the Zuni Kidney Project |
| Q35809946 | Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics |
| Q91727269 | Effects of Propolis Extract and Propolis-Derived Compounds on Obesity and Diabetes: Knowledge from Cellular and Animal Models |
| Q48479771 | Employing in vitro analysis to test the potency of methylglyoxal in inducing the formation of amyloid-like aggregates of caprine brain cystatin |
| Q49787990 | Endothelial Cell Metabolism. |
| Q34324055 | Endothelial Na+/H+ exchanger NHE1 participates in redox-sensitive leukocyte recruitment triggered by methylglyoxal |
| Q38082465 | Endothelial dysfunction in (pre)diabetes: characteristics, causative mechanisms and pathogenic role in type 2 diabetes |
| Q41964977 | Energy metabolism, altered proteins, sirtuins and ageing: converging mechanisms? |
| Q46427869 | Enhanced Aerobic Glycolysis by S-Nitrosoglutathione via HIF-1α Associated GLUT1/Aldolase A Axis in Human Endothelial Cells |
| Q90655613 | Enhancement of glyoxalase 1, a polyfunctional defense enzyme, by quercetin in the brain in streptozotocin-induced diabetic rats |
| Q55104216 | Eucommia ulmoides Ameliorates Glucotoxicity by Suppressing Advanced Glycation End-Products in Diabetic Mice Kidney. |
| Q35673589 | Evaluation of potential flavonoid inhibitors of glyoxalase-I based on virtual screening and in vitro studies |
| Q24630049 | GLO1 overexpression in human malignant melanoma |
| Q85210614 | Genetics of diabetes complications |
| Q36861036 | Glucolipotoxicity: fuel excess and beta-cell dysfunction. |
| Q90632374 | Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease |
| Q46717230 | Glycation-induced inactivation of aspartate aminotransferase, effect of uric acid. |
| Q64071600 | Glycine Suppresses AGE/RAGE Signaling Pathway and Subsequent Oxidative Stress by Restoring Glo1 Function in the Aorta of Diabetic Rats and in HUVECs |
| Q92066220 | Glycine increases glyoxalase-1 function by promoting nuclear factor erythroid 2-related factor 2 translocation into the nucleus of kidney cells of streptozotocin-induced diabetic rats |
| Q35813624 | Glycoxidation and diabetic complications: modern lessons and a warning? |
| Q51345459 | Glyoxalase 1 enzyme activity in erythrocytes and Ala111Glu polymorphism in type 1-diabetes patients. |
| Q24613178 | Glyoxalase 1 increases anxiety by reducing GABAA receptor agonist methylglyoxal |
| Q92646117 | Glyoxalase 1, regulated by LncRNA MALAT1, promotes malignant development of esophageal squamous cell carcinoma |
| Q42362227 | Glyoxalase 1-knockdown in human aortic endothelial cells - effect on the proteome and endothelial function estimates |
| Q36576306 | Glyoxalase I activity and immunoreactivity in the aging human lens |
| Q46966682 | Glyoxalase I is critical for human retinal capillary pericyte survival under hyperglycemic conditions |
| Q39884842 | Glyoxalase I overexpression ameliorates renal ischemia-reperfusion injury in rats |
| Q38311623 | Glyoxalase II, a detoxifying enzyme of glycolysis byproduct methylglyoxal and a target of p63 and p73, is a pro-survival factor of the p53 family |
| Q53085119 | Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes. |
| Q46790327 | Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans |
| Q46951415 | Heat-shock protein 27 is a major methylglyoxal-modified protein in endothelial cells |
| Q35436475 | High glucose, glucose fluctuation and carbonyl stress enhance brain microvascular endothelial barrier dysfunction: Implications for diabetic cerebral microvasculature |
| Q36233220 | Human glyoxalase II contains an Fe(II)Zn(II) center but is active as a mononuclear Zn(II) enzyme |
| Q33773237 | Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress |
| Q37120159 | Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer |
| Q39331191 | Hypoxia driven glycation: Mechanisms and therapeutic opportunities. |
| Q45712472 | Identification of alpha-dicarbonyl scavengers for cellular protection against carbonyl stress |
| Q57110548 | Immunomodulation by Processed Animal Feed: The Role of Maillard Reaction Products and Advanced Glycation End-Products (AGEs) |
| Q43674559 | In situ kinetic analysis of glyoxalase I and glyoxalase II in Saccharomyces cerevisiae. |
| Q39451237 | Increased glyoxalase I levels inhibit accumulation of oxidative stress and an advanced glycation end product in mouse mesangial cells cultured in high glucose |
| Q92783034 | Indole-4-carboxaldehyde Isolated from Seaweed, Sargassum thunbergii, Attenuates Methylglyoxal-Induced Hepatic Inflammation |
| Q33816297 | Induction of diabetes in aged C57B6 mice results in severe nephropathy: an association with oxidative stress, endoplasmic reticulum stress, and inflammation |
| Q36001244 | Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells |
| Q42699855 | Inhibition of Methylglyoxal-Mediated Protein Modification in Glyoxalase I Overexpressing Mouse Lenses |
| Q38563967 | Inhibitory effects and actions of pentacyclic triterpenes upon glycation |
| Q34248342 | Inositols prevent and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and by scavenging superoxide. |
| Q39854329 | Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials |
| Q39107278 | Loss of Glyoxalase 1 Induces Compensatory Mechanism to Achieve Dicarbonyl Detoxification in Mammalian Schwann Cells |
| Q43117950 | Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina |
| Q37857087 | Macrovascular angiopathy in children and adolescents with type 1 diabetes. |
| Q47303198 | Maillard Proteomics: Opening New Pages |
| Q73040201 | Maillard reactions by alpha-oxoaldehydes: detection of glyoxal-modified proteins |
| Q48667618 | Mangiferin Upregulates Glyoxalase 1 Through Activation of Nrf2/ARE Signaling in Central Neurons Cultured with High Glucose |
| Q33229504 | Mass spectrometry of advanced glycation end products |
| Q43272240 | Mesenchymal stem cell-like cells derived from mouse induced pluripotent stem cells ameliorate diabetic polyneuropathy in mice |
| Q44631210 | Metabolism, not autoxidation, plays a role in alpha-oxoaldehyde- and reducing sugar-induced erythrocyte GSH depletion: relevance for diabetes mellitus |
| Q43249355 | Methylglyoxal augments intracellular oxidative stress in human aortic endothelial cells. |
| Q54357761 | Methylglyoxal impairs endothelial insulin sensitivity both in vitro and in vivo. |
| Q34389881 | Methylglyoxal induces mitochondrial dysfunction and cell death in liver |
| Q39314131 | Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation |
| Q46325452 | Methylglyoxal mediates vascular inflammation via JNK and p38 in human endothelial cells |
| Q40329542 | Methylglyoxal modification of mSin3A links glycolysis to angiopoietin-2 transcription |
| Q37183293 | Methylglyoxal, diabetes mellitus and diabetic complications |
| Q35063131 | Methylglyoxal, the dark side of glycolysis |
| Q39042002 | Modulation of GSH with exogenous agents leads to changes in glyoxalase 1 enzyme activity in VL-17A cells exposed to chronic alcohol plus high glucose |
| Q43720970 | Modulation of glyoxalase, glutathione S-transferase and antioxidant enzymes in the liver, spleen and erythrocytes of mice by dietary administration of fenugreek seeds |
| Q42590459 | Modulation of the glyoxalase system in the aging model Podospora anserina: effects on growth and lifespan. |
| Q38096444 | Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products. |
| Q37530715 | NAD+ availability and proteotoxicity |
| Q37903708 | Naturally occurring inhibitors against the formation of advanced glycation end-products |
| Q33849766 | Negative consequences of glycation. |
| Q29616101 | Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage |
| Q34489018 | Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats |
| Q38111707 | Pathophysiology of the diabetic kidney. |
| Q55454896 | Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial. |
| Q37401263 | Pregabalin in the treatment of chronic pain: an overview |
| Q42013303 | Proanthocyanidin Attenuation of Oxidative Stress and NF- κ B Protects Apolipoprotein E-Deficient Mice against Diabetic Nephropathy |
| Q82814955 | Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology |
| Q42803262 | Protective effect of liquiritigenin against methylglyoxal cytotoxicity in osteoblastic MC3T3-E1 cells |
| Q37112969 | Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems--role in ageing and disease |
| Q37230025 | Proteome wide reduction in AGE modification in streptozotocin induced diabetic mice by hydralazine mediated transglycation |
| Q33289842 | Proteomic analysis defines altered cellular redox pathways and advanced glycation end-product metabolism in glomeruli of db/db diabetic mice |
| Q42048767 | Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry |
| Q34110891 | Reduced fructosamine-3-kinase activity and its mRNA in human distal colorectal carcinoma |
| Q37400729 | Reductive metabolism of AGE precursors: a metabolic route for preventing AGE accumulation in cardiovascular tissue |
| Q34336935 | Role for glyoxalase I in Alzheimer's disease. |
| Q36407601 | Role of Glyoxalase 1 (Glo1) and methylglyoxal (MG) in behavior: recent advances and mechanistic insights |
| Q35896615 | Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy |
| Q28588521 | Role of the glyoxalase system in astrocyte-mediated neuroprotection |
| Q34055011 | Role of vascular risk factors and vascular dysfunction in Alzheimer's disease |
| Q28545019 | S100A8/A9 stimulates keratinocyte proliferation in the development of squamous cell carcinoma of the skin via the receptor for advanced glycation-end products |
| Q43776154 | Suppression of methylglyoxal hyperactivity by mangiferin can prevent diabetes-associated cognitive decline in rats |
| Q30317530 | Temporal dynamics of glyoxalase 1 in secondary neuronal injury |
| Q24338430 | The Human hydroxyacylglutathione hydrolase (HAGH) gene encodes both cytosolic and mitochondrial forms of glyoxalase II |
| Q56760512 | The aldo-keto reductase superfamily and its role in drug metabolism and detoxification |
| Q46743346 | The effects of partial thiamin deficiency and oxidative stress (i.e., glyoxal and methylglyoxal) on the levels of alpha-oxoaldehyde plasma protein adducts in Fischer 344 rats |
| Q36716401 | The glucose metabolite methylglyoxal inhibits expression of the glucose transporter genes by inactivating the cell surface glucose sensors Rgt2 and Snf3 in yeast. |
| Q34436018 | The maillard reaction in eye diseases |
| Q84735970 | The metal ion requirements of Arabidopsis thaliana Glx2-2 for catalytic activity |
| Q46026413 | The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. |
| Q38200957 | The pathobiology of diabetic vascular complications--cardiovascular and kidney disease |
| Q37801857 | The pathogenic role of Maillard reaction in the aging eye. |
| Q37661644 | The proinflammatory cytokine high-mobility group box-1 mediates retinal neuropathy induced by diabetes |
| Q40797864 | The protection conferred against ischemia-reperfusion injury in the diabetic brain by N-acetylcysteine is associated with decreased dicarbonyl stress |
| Q34348813 | The role of AGEs in aging: causation or correlation |
| Q35649410 | The role of advanced glycation end products in the development of atherosclerosis |
| Q38394355 | The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases |
| Q36916418 | Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia |
| Q44525676 | Triosephosphates are toxic to superoxide dismutase-deficient Escherichia coli. |
| Q36245387 | Understanding RAGE, the receptor for advanced glycation end products |
| Q44590355 | Unusual susceptibility of heme proteins to damage by glucose during non-enzymatic glycation |
| Q83047854 | Upregulation of glyoxalase I fails to normalize methylglyoxal levels: a possible mechanism for biochemical changes in diabetic mouse lenses |
| Q36514906 | Uremic Toxicity of Advanced Glycation End Products in CKD. |
| Q39008557 | Vascular AGE-ing by methylglyoxal: the past, the present and the future |
| Q41660334 | Zebrafish as a Model for the Study of Microvascular Complications of Diabetes and Their Mechanisms |
| Q83105602 | [Current concepts of diabetic atherogenesis] |
| Q34440949 | α-Lipoic acid protects diabetic apolipoprotein E-deficient mice from nephropathy |
Search more.